Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study

被引:19
作者
Xiang, Yu-Tao [2 ,3 ]
Wang, Chuan-Yue [1 ,2 ]
Weng, Yong-Zhen [2 ]
Bo, Qi-Jing [2 ]
Chiu, Helen F. K. [3 ]
Chan, Sandra S. M. [3 ]
Lee, Edwin H. M. [3 ]
Ungvari, Gabor S. [4 ]
机构
[1] Beijing Anding Hosp, Lab Clin Psychopharmacol, Beijing 100088, Peoples R China
[2] Capital Med Univ, Beijing Anding Hosp, Beijing, Peoples R China
[3] Chinese Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China
[4] Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia
基金
中国国家自然科学基金;
关键词
Schizophrenia; Maintenance treatment; Relapse; Paranoid; China; MAINTENANCE TREATMENT; RISPERIDONE; RISK; HALOPERIDOL; ANTIPSYCHOTICS; PREVENTION; WITHDRAWAL; OLANZAPINE; EPISODE;
D O I
10.1007/s00127-010-0304-1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Relapse prevention is the main goal of maintenance treatment in schizophrenia. This study aimed to determine the rate and the socio-demographic and clinical predictors of relapse in Chinese schizophrenia patients following treatment of the acute phase of the illness. In a multi-center, randomized, controlled, longitudinal study, 404 patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to either the maintenance (i.e., initial optimal therapeutic doses continued throughout the study) or the dose-reduction group (i.e., initial optimal therapeutic doses continued for 4 or 26 weeks followed by a 50% dose reduction that was maintained until the end of the study). Participants were interviewed at entry using standardized assessment instruments, and followed up for 12-26 months. In univariate analyses, relapse was significantly associated with the membership of the dose-reduction group, poor medication adherence, and having a diagnosis of the paranoid type of schizophrenia. In Cox proportional-hazards regression analysis the membership of the dose-reduction group, poorer medication adherence, more severe drug-induced side effects and prominent paranoid symptoms independently predicted a higher risk of relapse. The study confirmed the importance of maintenance medication in preventing relapse in Chinese schizophrenia patients underscoring the risk of relapse associated with lack of treatment adherence, severe side effects and the patients' paranoid attitude. Socio-demographic characteristics were not associated with relapse in Chinese schizophrenia patients. Potential residual confounding caused by unmeasured variables should be fully considered in future studies.
引用
收藏
页码:1325 / 1330
页数:6
相关论文
共 42 条
[1]   Statistics notes - Concealing treatment allocation in randomised trials [J].
Altman, DG ;
Schulz, KF .
BRITISH MEDICAL JOURNAL, 2001, 323 (7310) :446-447
[2]  
[Anonymous], 1985, Psychopharmacol Bull M, V21, P1069
[3]  
BEISER M, 1994, AM J PSYCHIAT, V151, P857
[4]   A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients [J].
Chen, EYH ;
Hui, CLM ;
Dunn, ELW ;
Miao, MYK ;
Yeung, WS ;
Wong, CK ;
Chan, WF ;
Tang, WN .
SCHIZOPHRENIA RESEARCH, 2005, 77 (01) :99-104
[5]   A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia [J].
Csernansky, JG ;
Mahmoud, R ;
Brenner, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (01) :16-22
[6]  
Ding LJ, 2007, MED J CHIN PEOPLE HL, V19, P481
[7]   Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder [J].
Doering, S ;
Müller, E ;
Köpcke, W ;
Pietzcker, A ;
Gaebel, W ;
Linden, M ;
Müller, P ;
Müller-Spahn, F ;
Tegeler, J ;
Schüssler, G .
SCHIZOPHRENIA BULLETIN, 1998, 24 (01) :87-98
[8]   Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol:: 12-Month follow-up of the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study [J].
Dossenbach, M ;
Arango-Dávila, C ;
Ibarra, HS ;
Landa, E ;
Aguilar, J ;
Caro, O ;
Leadbetter, J ;
Assunçao, S .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (08) :1021-1030
[9]   Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia [J].
Gaebel, Wolfgang ;
Riesbeck, Mathias .
SCHIZOPHRENIA RESEARCH, 2007, 95 (1-3) :19-29
[10]  
GILBERT PL, 1995, ARCH GEN PSYCHIAT, V52, P173